Trials / Completed
CompletedNCT00995787
Safety and Tolerability of AZD1656 in Type 2 Diabetes Mellitus (T2DM) Patients Treated With Metformin and Sulfonylurea
A Randomized, Single-blind, Placebo-controlled, Phase I Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD1656 Compared to Placebo in T2DM Patients Treated With Metformin and Sulfonylurea
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 75 (actual)
- Sponsor
- AstraZeneca · Industry
- Sex
- All
- Age
- 30 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The primary aim of this study is to evaluate the safety and tolerability of AZD1656 in T2DM patients treated with metformin and sulfonylurea.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AZD1656 | Dose titration of oral suspension of AZD165 during 3 days to a tolerable dose given twice daily. Subjects will thereafter be treated with this dose twice daily for another 6 days |
| DRUG | Placebo | Dose titration of oral suspension of placebo during 3 days given twice daily. Subjects will thereafter be for another 6 days |
Timeline
- Start date
- 2009-10-01
- Primary completion
- 2010-02-01
- Completion
- 2010-02-01
- First posted
- 2009-10-15
- Last updated
- 2010-02-26
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00995787. Inclusion in this directory is not an endorsement.